EF Hutton Acquisition Co. I reaffirmed their buy rating on shares of VolitionRx (NYSEAMERICAN:VNRX – Get Rating) in a report published on Thursday, Benzinga reports. They currently have a $6.00 price objective on the medical research company’s stock.
Separately, Benchmark cut shares of VolitionRx from a buy rating to a hold rating in a research note on Wednesday, February 1st. They noted that the move was a valuation call.
VolitionRx Trading Up 3.5 %
VNRX opened at $1.78 on Thursday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.04 and a current ratio of 1.04. The stock has a market capitalization of $103.49 million, a price-to-earnings ratio of -3.12 and a beta of 1.73. VolitionRx has a twelve month low of $1.31 and a twelve month high of $3.30.
Institutional Trading of VolitionRx
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Cerity Partners LLC purchased a new position in VolitionRx in the 4th quarter worth approximately $92,000. Lagoda Investment Management L.P. grew its stake in VolitionRx by 15.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 3,755,045 shares of the medical research company’s stock worth $9,125,000 after buying an additional 498,300 shares in the last quarter. Creative Planning purchased a new position in VolitionRx in the 4th quarter worth approximately $32,000. Cowen Prime Advisors LLC grew its stake in VolitionRx by 83.2% in the 4th quarter. Cowen Prime Advisors LLC now owns 177,043 shares of the medical research company’s stock worth $430,000 after buying an additional 80,412 shares in the last quarter. Finally, Spectrum Asset Management Inc. NB CA purchased a new position in VolitionRx in the 4th quarter worth approximately $135,000. Institutional investors own 10.30% of the company’s stock.
VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.
- Get a free copy of the StockNews.com research report on VolitionRx (VNRX)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.